Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

George Reader

Interventional Cardiology Wichita, KS Medical Doctor

NPI 1508812744 CMS profile 204307

9840 E 21St St N, Wichita, KS 67206

Open in the dashboard

General payments

$4,129

272 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, George Reader of Wichita, KS is reported in the CMS Open Payments database as having received $4,129 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $277 16
2022 General $959 61
2021 General $1,443 99
2020 General $794 53
2019 General $656 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Reader
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to George Reader were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year George Reader Interventional Cardiology median Middle half National median
2019 $656 $1,097 $329–$3,048 $163
2020 $794 $473 $161–$1,480 $114
2021 $1,443 $677 $233–$1,827 $132
2022 $959 $978 $333–$2,724 $149
2023 $277 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $542 48 payments
  2. Amgen Inc. $469 30 payments
  3. AstraZeneca Pharmaceuticals LP $409 26 payments
  4. Merck Sharp & Dohme Corporation $375 26 payments
  5. Novartis Pharmaceuticals Corporation $352 24 payments
  6. Abbott Laboratories $249 9 payments
  7. Sanofi-Aventis U.S. LLC $200 15 payments
  8. Esperion Therapeutics, Inc. $182 13 payments
  9. Amarin Pharma Inc. $176 11 payments
  10. Pfizer Inc. $135 9 payments
  11. Other $1,040 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,108 271 payments
  2. Education $22 1 payment
Products named General payments · program years 2019–2023
  1. XARELTO $542 48 payments
  2. Repatha $469 30 payments
  3. VERQUVO $375 26 payments
  4. ENTRESTO $320 22 payments
  5. FARXIGA $316 20 payments
  6. NEXLETOL $182 13 payments
  7. Vascepa $176 11 payments
  8. Confirm Rx $165 6 payments
  9. Corlanor $148 10 payments
  10. PRALUENT $120 6 payments
  11. Other $1,760 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

118

Median for Interventional Cardiology: 2,236

Drug cost

$1,234

Median for Interventional Cardiology: $380,412

Branded share of claims

28.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Labetalol Hcl Generic 23 $480
Amiodarone Hcl Generic 25 $262
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 15 $246
Atorvastatin Calcium Generic 36 $151
Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide Brand 19 $94

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record